Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal

Autor: Thompson, Alan, Carroll, William, Ciccarelli, Olga, Comi, Giancarlo, Cross, Anne H., Donnelly, Alexis A., Feinstein, Anthony, Fox, Robert J, Helme, Anne, Hohlfeld, Reinhard, Hyde, Robert, Kanellis, Pamela, Landsman, Douglas, Lubetzki, Catherine, Marrie, Ruth Ann, Morahan, Julia, Montalban, Xavier, Musch, Bruno, Rawlings, Sarah, Salvetti, Marco, Sellebjerg, Finn, Sincock, Caroline, Smith, Kathryn E, Strum, Jon, Zaratin, Paola, Coetzee, Timothy, Universitat Autònoma de Barcelona

Publikováno v: Thompson, A J, Carroll, W, Ciccarelli, O, Comi, G, Cross, A, Donnelly, A, Feinstein, A, Fox, R J, Helme, A, Hohlfeld, R, Hyde, R, Kanellis, P, Landsman, D, Lubetzki, C, Marrie, R A, Morahan, J, Montalban, X, Musch, B, Rawlings, S, Salvetti, M, Sellebjerg, F, Sincock, C, Smith, K E, Strum, J, Zaratin, P & Coetzee, T 2022, ' Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal ', Multiple Sclerosis Journal, vol. 28, no. 1, pp. 16-28 . https://doi.org/10.1177/13524585211059766
Multiple Sclerosis (Houndmills, Basingstoke, England)

Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d2ee819650ab1ddacd2946753c187e1
https://ddd.uab.cat/record/275819

Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.

Autor: Thompson AJ; University College London, London, UK., Carroll W; The University of Western Australia, Perth, WA, Australia., Ciccarelli O; University College London, London, UK., Comi G; Vita-Salute San Raffaele University, Milan, Italy., Cross A; Washington University in St. Louis, St. Louis, MO, USA., Donnelly A; International Progressive MS Alliance, Dublin, Ireland., Feinstein A; Sunnybrook Research Institute, Toronto, ON, Canada., Fox RJ; Cleveland Clinic, Cleveland, OH, USA., Helme A; MS International Federation, London, UK., Hohlfeld R; Munich Cluster for Systems Neurology, Ludwig Maximilian University of Munich, Munich, Germany., Hyde R; Biogen, Cambridge, MA, USA., Kanellis P; MS Society of Canada, Toronto, ON, Canada., Landsman D; National Multiple Sclerosis Society, New York, NY, USA., Lubetzki C; Salpêtrière Hospital, Paris, France., Marrie RA; University of Manitoba, Winnipeg, MB, Canada., Morahan J; MS Research Australia, North Sydney, NSW, Australia., Montalban X; Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Musch B; Genentech, San Francisco, CA, USA., Rawlings S; MS Society, London, UK., Salvetti M; Department of Neurosciences, Mental Health and Sensory Organs, Centre for Experimental Neurological Therapies (CENTERS), Sapienza University of Rome, Rome, Italy/Istituto Neurologico Mediterraneo (INM) Neuromed, Pozzilli, Italy., Sellebjerg F; Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark., Sincock C; International Progressive MS Alliance, Glasgow, UK., Smith KE; International Progressive MS Alliance, Lyme, CT, USA., Strum J; International Progressive MS Alliance, Los Angeles, CA, USA., Zaratin P; Italian Multiple Sclerosis Foundation, Genoa, Italy., Coetzee T; National Multiple Sclerosis Society, New York, NY, USA.

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Jan; Vol. 28 (1), pp. 16-28. Date of Electronic Publication: 2021 Dec 01.